Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The funding was led by Hangzhou Point Investment Management, with a contribution from Lingdu Capital. The proceeds will be used for research and development investment and the acquisition of an industrialization plant. Eyougene expects to initiate its third financing round in June of this year.
Company Overview and Strategic Focus
Founded in 2018, Eyougene has quickly established itself as a leading CDMO with a high-profile clientele that includes Merck, Hengrui Pharmaceuticals, BASF, Mitsubishi Chemical, and others. The company’s acquisition of a cGMP-aligned industrialization plant in Hangzhou at the end of 2022 further strengthens its capabilities in manufacturing and quality control. This strategic move underscores Eyougene’s commitment to expanding its operations and enhancing its service offerings.
Future Outlook
The Series B financing round positions Eyougene to accelerate its growth and expand its presence in the CDMO market. With robust financial backing and a strong client base, Eyougene is poised to drive innovation in digital CDMO services. The proceeds will support the company’s R&D initiatives and enhance its industrialization capabilities, further solidifying its position as a leader in the industry. The planned third financing round in June of this year highlights Eyougene’s ongoing commitment to strategic expansion and growth.-Fineline Info & Tech
